Serum Vitamin D Levels in Chronic Hepatitis B Patients Before and During Treatment.
Chronic liver disease
antiviral therapy
hepatitis B
lamivudine
serum
vitamin D levels
Journal
Infectious disorders drug targets
ISSN: 2212-3989
Titre abrégé: Infect Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269158
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
06
2019
revised:
04
10
2019
accepted:
04
11
2019
pubmed:
14
11
2019
medline:
10
9
2021
entrez:
14
11
2019
Statut:
ppublish
Résumé
Hepatitis B is a potentially life-threatening liver infection and it is a major global health problem. Over the past decade, numerous studies have reported that patients with CLD, especially HCV-positive and HBV-positive patients, have decreased 25(OH) D levels. The current study was designed to assess the serum levels of vitamin D [25(OH) D3] in chronic hepatitis B patients, before and during treatment with antiviral therapy. It was a prospective study in which 80 subjects were enrolled between December 2017 and June 2018. A total of 50 treatment-naïve chronic HBV patients and 30 healthy subjects were recruited. The studied cases received treatment in the form of Lamivudine 100 mg tablet, once daily. Full routine laboratory investigations, HBV DNA measurement by real-time PCR were conducted once before initiation of antiviral treatment and again at least 6 months later. Serum vitamin D level [25(OH)D3 was assessed twice, once before initiation of antiviral treatment and again at least 6 months later. This was done for all the patients enrolled in the study. The studied cases showed a significantly low mean serum Vitamin D level when assessed before treatment (21.6 ± 5.8 ng/ml), compared to the level after 6 ms of treatment (31.1 ± 7.3 ng/ml) which was comparable to that of the control group (33.4 ± 5 ng/ml). The present study highlights the impact of antiviral therapy on vitamin D deficiency in CHB patients, where effective therapy improves vitamin D levels. Meanwhile, it is recommended to study the impact of vitamin D replacement and correction on the disease progression or regression.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
Hepatitis B is a potentially life-threatening liver infection and it is a major global health problem. Over the past decade, numerous studies have reported that patients with CLD, especially HCV-positive and HBV-positive patients, have decreased 25(OH) D levels. The current study was designed to assess the serum levels of vitamin D [25(OH) D3] in chronic hepatitis B patients, before and during treatment with antiviral therapy.
METHODS
METHODS
It was a prospective study in which 80 subjects were enrolled between December 2017 and June 2018. A total of 50 treatment-naïve chronic HBV patients and 30 healthy subjects were recruited. The studied cases received treatment in the form of Lamivudine 100 mg tablet, once daily. Full routine laboratory investigations, HBV DNA measurement by real-time PCR were conducted once before initiation of antiviral treatment and again at least 6 months later. Serum vitamin D level [25(OH)D3 was assessed twice, once before initiation of antiviral treatment and again at least 6 months later. This was done for all the patients enrolled in the study.
RESULTS
RESULTS
The studied cases showed a significantly low mean serum Vitamin D level when assessed before treatment (21.6 ± 5.8 ng/ml), compared to the level after 6 ms of treatment (31.1 ± 7.3 ng/ml) which was comparable to that of the control group (33.4 ± 5 ng/ml).
CONCLUSION
CONCLUSIONS
The present study highlights the impact of antiviral therapy on vitamin D deficiency in CHB patients, where effective therapy improves vitamin D levels. Meanwhile, it is recommended to study the impact of vitamin D replacement and correction on the disease progression or regression.
Identifiants
pubmed: 31721718
pii: IDDT-EPUB-102261
doi: 10.2174/1871526519666191112112903
doi:
Substances chimiques
Antiviral Agents
0
Vitamin D
1406-16-2
Lamivudine
2T8Q726O95
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
840-847Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.